⁦Raza Bokhari⁩ ⁦Medicus Pharma Ltd⁩ Chairman & CEO ⁦The White House⁩ Congressional picnic June 12th 2025

⁦Raza Bokhari⁩ ⁦Medicus Pharma Ltd⁩ presenting #Bio international Boston June 17th 2025

$MDCX submitted to the FDA a plan to break new ground in veterinary oncology targeting a ~$250M market with 7-year market exclusivity, post approval Raza Bokhari dvm360.com/view/investiga…

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer newsfilecorp.com/release/256436… #Chemicals #Banking #Biotechnology #FinancialServices #InvestmentBanking #Appointment #NASDAQ #Investing

In an exclusive with ONCOLife, Dr. Raza Bokhari , CEO of Medicus Pharma $MDCX provides update on our game-changing treatment for skin cancer. Learn more about this potential  #unicorn & market disrupter in development Full story here d2ghdaxqb194v2.cloudfront.net/2893/197717.pdf #skincancer

Game changer: Medicus Pharma (NASDAQ:$MDCX) enters into a definitive agreement to acquire Antev, LTd, developing #Teverelixtargeting AUR and high CV risk prostate cancer. newsfilecorp.com/release/257255

Another milestone! Medicus Pharma CEO Raza Bokhari announces a definitive agreement to acquire Antev Ltd. UK— 2nd acquisition for Medicus Pharma!  Watch full interview here: proactiveinvestors.com/companies/news…

Type C meeting request with FDA submitted with an aim to fast track D-MNA development to treat BCC. Read full press release here: newsfilecorp.com/release/258042… Raza Bokhari

Interview full of strategic steps and how we at Medicus Pharma strive to improve patient outcomes by acquiring best-in-class treatment modalities. Updates on Skinject and Antev/Teverelix. Interview from May 12, 2025. Thank you, NASDAQ for having Raza Bokhari at your studio! Watch

Medicus Pharma CEO, Dr Raza Bokhari, MD to participate in a Fireside chat during the BTIG Virtual Biotech Conference 2025.   Raza Bokhari newsfilecorp.com/release/259382…

Medicus Pharma Ltd. announces voting results following the Annual and Special Meetings of the Shareholders. Read full press release here: Raza Bokhari newsfilecorp.com/release/259702…

Dr Raza Bokhari discusses key developments following the company’s Annual and Special meetings of shareholders. Two new board members- The Honorable Cathy McMorris Rodgers, veteran public servant with more than three decades of leadership experience. Also joining the board is

Interview with Pharmaphorum is now available to watch. Medicus Pharma CEO, Dr Raza Bokhari talks about Skinject and its delivery mechanism, phase 2 study, provides updates on Antev Ltd acquisition. Raza Bokhari   More details here: pharmaphorum.com/oncology/takin…

Medicus Pharma Ltd. and Helix Nanotechnologies Ltd to develop next generation thermostable infectious diseases vaccines!  Raza Bokhari Full story:  newsfilecorp.com/release/261071…

Medicus Pharma Ltd is breaking new ground and expanding the possibilities of Skinject technology. Raza Bokhari, CEO of Medicus Pharma Ltd. shares details on our newest collaboration with HelixNano in latest interview with Proactive. Watch full interview here:  youtube.com/watch?v=VLV6FN…

Drug Development & Delivery highlight of Medicus Pharma Ltd and Helix nano MOU focused on unlocking the potential of developing thermostable infectious diseases vaccines.  Raza Bokhari   Full story here: drug-dev.com/medicus-pharma…

biotechnation.com/episodes/a-new… Raza Bokhari

Medicus Pharma Ltd fundamentals are strong as ever. Seventy five percent of 90 patients are randomized in our novel phase 2 study to non-invasively treat Skin cancer. $MDCX is on track to close Antev acquisition and exploring joint venture with Helixnano to co-develop thermostable mRNA

CEO of Medicus Pharma Ltd joined Proactive to discuss latest developments.  Dr Bokhari talked about Type C meeting with the FDA, patient enrollment, and much more. Company’s fundamentals are strongest they have ever been- cash balance sheet, pace and progress of clinical development